Impact of Lipoprotein(a) on Valvular and Cardiovascular Outcomes in Patients With Calcific Aortic Valve Stenosis
In patients with CAVS, Lp(a) levels predicted a higher risk of valvular and cardiovascular outcomes. The impact of Lp(a)-lowering therapies on valvular and cardiovascular health should be assessed in a long-term randomized clinical trial.
Authors
- Audrey Paulin (ORCID: https://orcid.org/0000-0002-1224-9538)
- Philippe Pîbarot (ORCID: https://orcid.org/0000-0002-3607-279X)
- Marie-Annick A Clavel (ORCID: https://orcid.org/0000-0002-8924-740X)
- Hasanga D. Manikpurage (ORCID: https://orcid.org/0000-0002-2365-6956)
- Sébastien Thériault (ORCID: https://orcid.org/0000-0003-1893-8307)
- Benoît J. Arsenault (ORCID: https://orcid.org/0000-0003-2240-8456)
- Patrick Mathieu (ORCID: https://orcid.org/0000-0002-3805-2004)
- John H. Krege (ORCID: https://orcid.org/0000-0003-3914-0951)
- Arnaud Girard (ORCID: https://orcid.org/0000-0002-8219-9118)
- Emma Lajeunesse
Institutions
- Eli Lilly (Singapore) (SG)
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Université Laval (CA)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-03-13
- DOI
- https://doi.org/10.1161/jaha.124.038955
- Citations
- 5
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.94